Trial · NCT07465029
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 25
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS) | Up to 5-years | |
| Primary | Prevalence of transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS) | Up to 5-years | |
| Secondary | Proportion of participants receiving each first-line treatment category | Up to 5-years | Treatment categories include: * Erythropoiesis-stimulating agents (ESA) * Luspateracept * Hypomethylating agents (HMAs) * Lenalidomide * Conservative management (red-blood cell (RBC) transfusions without disease modifying therapy) |
| Secondary | Proportion of participants by treatment category at each line of therapy | Up to 5-years | Treatment category received at each line of therapy (first line, second line, third line and beyond), categorized as erythropoiesis-stimulating agents (ESA), luspatercept, hypomethylating agents (HMA), lenalidomide, or conservative management (red blood cell transfusions without disease-modifying therapy). Treatment sequences will be derived from retrospective medical chart abstraction of documented treatment start and stop dates. |
| Secondary | Treatment duration (time from initiation to discontinuation) of first-line treatment | Up to 5-years | |
| Secondary | Defined as number of RBC units received per participant per 8-weeks | Up to 5-years | |
| Secondary | Number and Rate of Healthcare Resource Utilization Events | Up to 5-years | Healthcare resource utilization events, including primary care visits, specialist visits, outpatient visits all-cause hospitalizations, transfusion-related hospitalizations, general laboratory tests, number of prescriptions related to transfusion-dependent lower-risk myelodysplastic syndromes, red blood cell transfusions, use of concomitant medicines related to other comorbidities as documented in participant medical records. |
| Secondary | Number of participants that achieve hematologic improvement-erythroid (HI-E) | Up to 5-years | |
| Secondary | Number of participants that achieve red-blood cell (RBC) transfusion independence (TI) | Up to 5-years | |
| Secondary | Number of participants that experience a change in transfusion burden (change in number of red-blood cell units received per 8-weeks) | Up to 5-years | |
| Secondary | Number of participants that progress to higher-risk myelodysplastic syndromes (MDS) | Up to 5-years | |
| Secondary | Number of participants that progress to acute myeloid leukemia (AML) | Up to 5-years | |
| Secondary | Number of participants that do not respond to first-line treatment | Up to 5-years | |
| Secondary | Number of participants that experience loss of response/secondary failure after an initial hematologic response | Up to 5-years | |
| Secondary | Cause of death | Up to 5-years | |
| Secondary | Serious adverse events (SAEs) | Up to 5-years | |
| Secondary | Number of serious cardiovascular events requiring emergency room visit or hospitalization | Up to 5-years | Cardiovascular events include: will include acute myocardial infarction or acute coronary syndrome, heart failure decompensation, clinically significant arrhythmias (including atrial fibrillation/flutter and ventricular arrhythmia), stroke or transient ischemic attack, and venous thromboembolism. |
| Secondary | Participant age | Baseline | |
| Secondary | Participant sex | Baseline | |
| Secondary | Year of first-line treatment initiation | Baseline |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07465029/registered